LANCL2
| Official symbol: | LANCL2 |
| Full name: | LanC like 2 |
| Location: | 7p11.2 |
| Also known as: | TASP, GPR69B |
| Entrez ID: | 55915 |
| Ensembl ID: | ENSG00000132434 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.87 (Driver) | | Gscore (Del): | 0.00 |
|
|
| Recurrently amplified in 3 cancer type(s) | |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 7 |
|
|
| Fusions detected in 4 cancer type(s) |
|
| |
|
|
|
| Functional class: | Not specified |
| JensenLab PubMed score: | 15.85 (Percentile rank: 43.67%) |
| PubTator score: | 24.53 (Percentile rank: 55.92%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | N/A |
| Tractability (antibody): | Predicted Tractable - High confidenceTargets located in the plasma membrane; Targets with GO cell component terms plasma membrane or secreted |
